Amanda L. Rinkenbaugh

Early temporal transcriptional and cytokine responses distinguish chemotherapy sensitivity in patient-derived xenograft models of triple-negative breast cancer.

Chemotherapy remains the backbone of neoadjuvant treatment for triple-negative breast cancer (TNBC), and response to chemotherapy strongly correlates with patient prognosis. However, predicting chemoresistance remains a major clinical challenge. To address this obstacle, we performed serial fine needle aspirations foll...